1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65CF146AE39E6B126852579410062B177
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-science-liaison-services-insights-for-evolving-msl-roles-responsibilities!OpenDocument
18
19OpenDocument
2054.210.61.41
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Medical Science Liaison Services Excellence: Generating Value for Diverse Customer Groups

ID: PSM-279


Features:

41 Info Graphics

73 Data Graphics

350+ Metrics

28 Narratives

30+ Best Practices


Pages: 145


Published: Pre-2013


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Biopharmaceutical and medical device companies find it increasingly challenging to deliver exceptional services to a diverse set of customers that may include regional Thought Leaders, important Clinical Investigators, local Opinion Leaders, Payer and Government Thought Leaders, and various internal stakeholders.

Concerns about compliance and legal limitations are forcing companies to re-examine how their medical science liaisons and internal medical staff must work to build strong relationships with key customer groups and decision-makers.

Best Practices, LLC, has conducted research that seeks to examine how MSLs can provide greater value through their work with internal stakeholders and with external decision-makers and leaders.

Specifically, this primary research identifies valuable insights into MSL services structure as well as the roles and responsibilities of these services. The study offers powerful insights that you will be able to use in the organization and deployment of your MSLs. Additionally, the new report will provide information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape.

Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Advanced Biohealing; Allergan; Amylin; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cephalon; EndoPharma; Eisai; Gambro; G.E. Healthcare; Genetech; GlaxoSmithKline; Ironwood Pharma; Kadmon Pharma; Laboratorios Esteve; Lantheus Medical Imaging; Metronic; Merck Sharp and Dohme; Novartis; Novo Nordisk; Onyx Pharma; Pfizer; QLT; Quidel; Shire; Takeda; Theravance; UCB


Study Snapshot

The report is based on research and information provided by 35 Pharmaceutical and Medical Device executives from 30 different companies.

Also, the study includes both large, established and small, emerging Pharmaceutical and Medical Device companies to provide broadest insights.

Key Findings

MSLs Expected to Work More Regularly with Other Internal Groups: Sales Reps and Professional Relations/Advocacy are the two groups that will be served most regularly (59 and 38%, respectively from survey). Surprisingly, 25% of companies say they do not serve Payer Services, but a number of companies said they have specially trained MSLs to serve this role. Those companies tout it as an important service.

Limited Fear of Losing Access to KOLs: A little more than one-third of companies say the see a high risk of KOL’s home institutions curtailing MSL access to such opinion leaders. Some did point out that some MSLs are becoming “too commercial” in their touch points and that could negatively impact access if it continues.

Corporate Integrity Agreements and Lawsuits Viewed With Minimal Concern: Only 25% of companies see a “high risk” that a CIA or lawsuit will discourage companies from providing services to KOLs and attempting to collaborate with them in the next two years.

Regulatory Bodies Will Make It Harder to Work with or See KOLs: Of all the potential risk factors listed in the survey, this one caused the most alarm. Forty-one percent view a “high risk” and 34% view this as a “medium risk.” Only “KOL's home institution limit their ability to see MSLs” garnered a higher combined risk score.


Table of Contents

  • Project Overview
  • MSL Services Key Insights
  • Key Opinion Leaders Management
  • MSL Internal Services and Activities
  • MSL Services and Payer Education and Support
  • MSL Services and Hospital/Health Care Access
  • Emerging Trends and Mitigating Risks
  • MSL Services and Physician Education
  • MSL Services and Patient Education and Advocacy Support
  • MSL Group Structure and Oversight
  • MSL Activities Throughout Life Cycle
  • MSL Services Best Practices and Voices from the Field